The global breast lesion guidance systems market is expected to witness significant growth over the forecast period. One-third of breast cancer diagnosed annually throughout the world is nonpalpable, and that level is likely to increase because of the greater implementation of screening programs as well as more advanced modalities, such as MRI, which pick up more clinically occult lesions.
According to the World Cancer Research Fund International, breast cancer is the most common cancer in women with an estimated 1.7 million new cases diagnosed in 2012. The highest incidence of breast cancer was in North America and Oceania. The incidence of breast cancer in North America was estimated at 80 per 100,000 individuals in Canada and around 92 per 100,000 in the U.S.
This shocking rise in the incidence of breast cancer has resulted in increasing awareness about the disease among women and a rise in the number of screening and imaging techniques in the market. Early detection of the malignancy of palpable and non-palpable breast lesions can result in effective and timely treatment of various breast abnormalities. This is one of the major factors driving the global breast lesion guidance systems market.
The increasing response toward the limitations of conventional localization methods identified by surgeons has increased the demand for alternative techniques of breast lesion localization. Technical challenges relating to deletion and same-day wire placement have led to the development of advanced breast lesion regulation systems. The favorable compensation scenario for breast cancer treatment in several developed countries, the increase in the number of breast cancer surgeries, and the promising ongoing research in the field have also contributed to the growth of the market.
Global Breast Lesion Guidance Systems Market: Trends and Opportunities
The favorable compensation situation for breast cancer treatment in several developed countries, the increase in the number of breast cancer surgeries, and the promising ongoing research in the field have also contributed to the growth of the market.
However, regulatory approval procedures are lengthy and complex due to the risks associated with several breast lesion localization devices. This is likely to hamper the growth of the global market. Success in eliminating these risks and producing safer localization devices is thus a major opportunity for players operating in the global market.
Global Breast Lesion Guidance Systems Market: Treatment Outlook
The most broadly used breast lesion guidance systems include wire-guided localization (WGL)-WGL involves the insertion of a wire to the center of the lesion. Magnetic tracers, electromagnetic reflectors, and radioisotope localization methods such as radio-guided occult lesion localization (ROLL)-The ROLL method is a new technique for the localization and removal of non-palpable lesions. It involves the intratumoral insertion of a radioactive tracer. and radioactive seed localization (RSL)- In the RSL technique, an iodine seed is fixed in the center of the tumor.
On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, Middle East, and the Rest of the world. The global market is expected to grow till 2025 from 2019. North America is expected to have the largest share in the market which is then followed by Europe. This is because of increasing diseased personnel, government funding and awareness among people.
The Major key players operating in the breast lesion guidance systems market are Becton, Dickinson and Company, C.R. Bard, Inc., Devicor Medical Products Inc., and Hologic Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.